US20150133853A1 - Intravascular nano-bubbling oxygenator - Google Patents
Intravascular nano-bubbling oxygenator Download PDFInfo
- Publication number
- US20150133853A1 US20150133853A1 US14/602,260 US201514602260A US2015133853A1 US 20150133853 A1 US20150133853 A1 US 20150133853A1 US 201514602260 A US201514602260 A US 201514602260A US 2015133853 A1 US2015133853 A1 US 2015133853A1
- Authority
- US
- United States
- Prior art keywords
- oxygenator
- bubbling
- nano
- intravascular
- tube wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/32—Oxygenators without membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1678—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes intracorporal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
- A61M2230/06—Heartbeat rate only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/50—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
- A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
- A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked
Definitions
- the annual mortality rate for all lung diseases is estimated to be approximately 250,000 in the US in 2000. About 150,000 patients were related to acute, potentially reversible respiratory failure and 100,000 patients related to chronic respiratory failure due to chronic obstructive lung disease (COPD) or chronic irreversible respiratory failure due to other illness. The estimated economic burden of these diseases is in the range of 72 billion dollars per year. The rate of death related to COPD has increased by 54%, and the World Health Organization (WHO) estimated that COPD will affect 5-15% of all adults in industrialized countries and accounting for 3 million deaths worldwide in 2020, as the 5 th most prevalent disease and the 3 rd leading cause of mortality.
- WHO World Health Organization
- the primary purpose of this design is to replace the oxygenation function of the diseased lung during acute or chronic lung function and ventilatory impairment. Because the exchange rate of CO 2 by the lungs is about 200 times more than that of oxygen, the oxygenation problem is the first and most serious clinical problem for us to face. Most of the clinical problems of CO 2 retention can be solved simply by the patients themselves or by the mechanical ventilation to increase the minute ventilation. So we simply focus on the resolutions for the main problem of acute, moderate to severe hypoxemia and chronic respiratory failure with long-term hypoxemia. Due to the improvement of biomaterial, the possibility to use normal pressure to hyperbaric nano-sized pure oxygen bubbles to improve oxygenation of the intracaval deoxygenated hemoglobin is reachable.
- the normal pressure to hyperbaric nano-bubbling intracaval oxygenator can replace the conventional mechanical ventilator, IVOX, IMO, and ECMO, to facilitate the oxygen demand of the patients.
- a low-flow intravenous oxygenator can replace conventional oxygen therapy system, improving the power and the motivation of patient activities.
- the invention is directed at the intravascular nano-bubbling oxygenator that utilizes an intravascular catheter with numerous nano-porous surface, in order to facilitate oxygen bubbles binding with the deoxygenated hemoglobin of the red cells in cardiovascular system.
- the inventions were designed to improve the clinical hypoxic patients with any kinds of acute or chronic reasons.
- the invention relates to the normal pressure to hyperbaric intravascular oxygenator, and more particularly to the different design of one lumen and multi lumens catheters with numerous nano-porous surface to facilitate nano-sized pure oxygen bubbles to the cardiovascular system.
- the primary purpose of the ventilation is to bring the air into and out the lungs, therefore oxygen can be added into the lungs and carbon dioxide can be removed.
- the volume of the pulmonary capillary circulation is about 150 ml, spreading over a surface area of approximately 750 square feet. This capillary surface area surrounds 300 million air sacs called alveoli.
- the deoxygenated venous return is oxygenated in less than one second in the pulmonary circulation due to huge capillary surface and extremely thin blood-alveolar barrier approximately one micrometer in distance. This allows the blood to be replenished with oxygen and for the excess carbon dioxide to be removed.
- Positive-pressure mechanical ventilation is a somewhat efficient and safe means for improving gas exchange in the patients with acute respiratory failure.
- serious adverse effects may occur with prolonged duration of intensive respiratory support or high oxygen fraction.
- These hazardous effects including oxygen toxicity, barotraumas, altered hormone and enzyme systems, mechanical ventilation induced lung injury (VILI), disuse atrophy of skeleton muscles, and added to the morbidity and mortality rates for these patients.
- VILI mechanical ventilation induced lung injury
- extracorporeal membrane oxygenation constitutes a mechanism for prolonged pulmonary bypass, which has been developed and optimized over several decades but has limited clinical utility today as a state-of-the-art artificial lung.
- the ECMO system includes an extra-corporeal pump and membrane system that performs a gas transfer across membranes.
- ECMO ECMO
- the limitations of ECMO include the requirement for a large and complex blood pump and oxygenator system, the necessity for a surgical procedure for cannulation, the need for systemic anticoagulation, the labor intensive implementation, the exceeding high cost, and a high rate of complications, including bleeding and infection, protein absorption, and platelet adhesion on the surface of the oxygenator membrane.
- the ECMO has become limited in its utility to select cases of neonatal respiratory failure, where reversibility is considered to be highly likely.
- IVOX intravenous membrane oxygenator
- the IVOX system has numerous limitations including a moderate rate of achievable gas exchange, difficulty in device implantation, a relatively high rate of adverse events, and a significant rate of device malfunctions, including blood-to-gas leaks due to broken hollow fibers.
- the present invention is to provide a normal pressure to hyperbaric nano-bubbling intravascular oxygenation system comprising a catheter with single or multiple lumens, a tube wall with numerous nano-sized pores on its surface, capable of being inserted into a blood vessel to transport gas.
- FIG. 1A , 1 B it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of one lumen type.
- FIG. 2A , 2 B it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multi lumens type.
- FIG. 3 it is the flowchart to illustrates the method for oxygenation.
- a partial porous catheter 110 comprises a tube wall 111 having lots of pores 112 .
- the catheter 110 is capable of being inserted into a blood vessel.
- the cross-section area of the catheter 110 is less than three fourths (3 ⁇ 4) of the cross-section area of the blood vessel.
- the length of the catheter 110 in a blood vessel varies from person to person depending on patient's body size.
- the catheter 110 comprises the biomaterial, such as, polymer, or ceramic, or metal, or composites.
- the tube wall 111 is hydrophobic and able to prevent bacterial colonization and thrombogenesis.
- the porous area portion of the tube wall 111 is five(5)% to ninety-five(95)% of the entire catheter in the blood vessel.
- the sizes of the pores are ranged from 0.3 nanometer to five hundred (500) micrometer.
- the catheter 110 includes one closed end and one opening end.
- the opening end is connected to a connector 120 .
- the connector 120 connects the catheter 110 and the gas transporting apparatus 130 .
- the gas transporting apparatus 130 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 120 .
- the gas transporting apparatus 130 comprises a flow adjustor 131 with a flow sensor (not shown), a pressure adjustor 132 with a barometer (not shown), a thermo adjustor 133 with a thermometer (not shown) for these range parameters.
- a pipe 140 connects the gas transporting apparatus 130 and a high pressure gas tank or any other container 142 with a regulator 141 .
- the gas is oxygen.
- the regulator 141 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator.
- the thermo adjustor 133 warms or cools the oxygen to a proper temperature
- the pressure adjuster 132 adjusts the pressure of the oxygen
- the flow adjustor 131 controls the flow rate of the oxygen.
- the oxygen passes the connector 120 to the tube 110 , and then distributes through the pores 112 to the blood.
- the pores 112 help produce bubbles in a range of nanometer to micrometer scale for range parameters when transporting gas.
- the control panel 150 calculates the feedback of the measurement of the blood oxygen concentration, vena caval pressure, heart rate, and temperature by one or one more detectors (not shown) and controls the gas transporting apparatus 130 for transporting gas at the specific range of temperature, pressure, and flowrate to the catheter 110 through the connector 120 .
- a partial porous catheter 210 comprises two lumens, one lumen tube wall 211 having lots of pores 212 , the other lumen tube wall 213 with or without pores, and a separating wall 214 to separate the tube 210 into the gas lumen 215 with pores on outer tube wall and the liquid lumen 216 with or without pores on the outer tube wall.
- Each of the gas lumen 215 and the liquid lumen 216 has an opening end with a removable cap (not shown) and the gas lumen 215 connects to a connector 220 .
- the other end of the liquid lumen 216 comprises an opening end to allow the guide wire or liquid passing through it.
- the other end of the gas lumen 215 comprises a closed end.
- the catheter 210 is capable of being inserted into a blood vessel.
- the cross-section area of the catheter 210 is less than three fourths (3 ⁇ 4) of the cross-section area of the blood vessel.
- the length of the catheter 210 in a blood vessel varies from person to person depending on patient's body size.
- the catheter 210 comprises the biomaterial, such as, polymer, or ceramic, or metal, or composites.
- the tube wall 211 and tube wall 213 are hydrophobic and able to prevent bacterial colonization and thrombogenesis.
- the porous area portion of the tube wall 211 or tube wall 213 is five(5) % or zero(0)% to ninety-five(95)% of the entire tube in the blood vessel.
- the sizes of the pores are ranged from 0.3 nanometer to five hundred (500) micrometer.
- the connector 220 connects the gas lumen 215 of the catheter 210 and the gas transporting apparatus 230 .
- the gas transporting apparatus 230 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 220 .
- the gas transporting apparatus 230 comprises a flow adjustor 231 with a flow sensor (not shown), a pressure adjustor 232 with a barometer (not shown), a thermo adjustor 233 with a thermometer (not shown) for range parameters.
- a pipe 240 connects the gas transporting apparatus 230 and a high pressure gas tank or any other container 242 with a regulator 241 .
- the gas is oxygen.
- the regulator 241 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator.
- the thermo adjustor 233 warms or cools the oxygen to a proper temperature
- the pressure adjuster 232 adjusts the pressure of the oxygen
- the flow adjustor 231 controls the flow rate of the oxygen for range parameters.
- the oxygen passes the connector 220 to the gas lumen 215 of the catheter 210 , and then distributes through the pores 212 to the blood.
- the pores 212 help produce bubbles in a range of nanometer to micrometer scale when transporting gas.
- the control panel 250 calculates the feedback of the measurement of the blood oxygen concentration, vena caval pressure, heart rate, or temperature by one or one more detectors (not shown) and controls the gas transporting apparatus 230 for transporting gas at the specific range of temperature, pressure, and flowrate to the gas lumen 215 of the catheter 210 through the connector 220 .
- a pressurized pure oxygen source is prepared.
- the oxygen source may be tank containing pressurized pure or high concentration oxygen.
- a gas transporting apparatus including a flow adjuster, a pressure adjuster, and a thermal adjuster to control the range parameters of the gas flow, temperature, and pressure of the oxygen, is connected to a gas lumen of a porous catheter with nano to micro-meter sized pores.
- the porous catheter is inserted into a blood vessel of a living body.
- the oxygen source is connected to the gas transporting apparatus.
- the gas transporting apparatus controls the distribution of the oxygen to the vascular system through the porous catheter.
- a blood oxygen concentration, a vena caval pressure, a heart rate, and a temperature of the living body are measured to as the control signals to feedback to the computer in a panel.
- the control signals are compared with the predetermined ranges set in the computer, and the panel sends commands to the gas transporting apparatus, and then back to the step 350 .
Abstract
The present invention provides a intravascular nano-bubbling oxygenator comprises a catheter, capable of being inserted into a blood vessel to transport normal pressure to hyperbaric gas, comprising: a tube wall with one or two lumens, and an opening end, wherein the tube wall partially comprises a plurality of pores; a connector; a gas transporting apparatus, and a control panel with on-line data sensors connections.
Description
- This is a Continuation application that claims priority to U.S. non-provisional application, application Ser. No. 11/868,528, filed Oct. 7, 2007, the entire contents of each of which are expressly incorporated herein by reference.
- A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to any reproduction by anyone of the patent disclosure, as it appears in the United States Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.
- The annual mortality rate for all lung diseases is estimated to be approximately 250,000 in the US in 2000. About 150,000 patients were related to acute, potentially reversible respiratory failure and 100,000 patients related to chronic respiratory failure due to chronic obstructive lung disease (COPD) or chronic irreversible respiratory failure due to other illness. The estimated economic burden of these diseases is in the range of 72 billion dollars per year. The rate of death related to COPD has increased by 54%, and the World Health Organization (WHO) estimated that COPD will affect 5-15% of all adults in industrialized countries and accounting for 3 million deaths worldwide in 2020, as the 5th most prevalent disease and the 3rd leading cause of mortality.
- The primary purpose of this design is to replace the oxygenation function of the diseased lung during acute or chronic lung function and ventilatory impairment. Because the exchange rate of CO2 by the lungs is about 200 times more than that of oxygen, the oxygenation problem is the first and most serious clinical problem for us to face. Most of the clinical problems of CO2 retention can be solved simply by the patients themselves or by the mechanical ventilation to increase the minute ventilation. So we simply focus on the resolutions for the main problem of acute, moderate to severe hypoxemia and chronic respiratory failure with long-term hypoxemia. Due to the improvement of biomaterial, the possibility to use normal pressure to hyperbaric nano-sized pure oxygen bubbles to improve oxygenation of the intracaval deoxygenated hemoglobin is reachable. In patients with acute respiratory failure, the normal pressure to hyperbaric nano-bubbling intracaval oxygenator can replace the conventional mechanical ventilator, IVOX, IMO, and ECMO, to facilitate the oxygen demand of the patients. In patients of chronic respiratory failure, a low-flow intravenous oxygenator can replace conventional oxygen therapy system, improving the power and the motivation of patient activities.
- The invention is directed at the intravascular nano-bubbling oxygenator that utilizes an intravascular catheter with numerous nano-porous surface, in order to facilitate oxygen bubbles binding with the deoxygenated hemoglobin of the red cells in cardiovascular system. The inventions were designed to improve the clinical hypoxic patients with any kinds of acute or chronic reasons.
- The invention relates to the normal pressure to hyperbaric intravascular oxygenator, and more particularly to the different design of one lumen and multi lumens catheters with numerous nano-porous surface to facilitate nano-sized pure oxygen bubbles to the cardiovascular system.
- Description of Related Arts
- The primary purpose of the ventilation is to bring the air into and out the lungs, therefore oxygen can be added into the lungs and carbon dioxide can be removed. The volume of the pulmonary capillary circulation is about 150 ml, spreading over a surface area of approximately 750 square feet. This capillary surface area surrounds 300 million air sacs called alveoli. The deoxygenated venous return is oxygenated in less than one second in the pulmonary circulation due to huge capillary surface and extremely thin blood-alveolar barrier approximately one micrometer in distance. This allows the blood to be replenished with oxygen and for the excess carbon dioxide to be removed.
- There have been numerous efforts in the past 40 years to achieve artificial ventilation function, such as negative pressure and positive pressure mechanical ventilator, and extracorporeal membrane oxygenator (ECMO).
- Positive-pressure mechanical ventilation is a somewhat efficient and safe means for improving gas exchange in the patients with acute respiratory failure. However, serious adverse effects may occur with prolonged duration of intensive respiratory support or high oxygen fraction. These hazardous effects, including oxygen toxicity, barotraumas, altered hormone and enzyme systems, mechanical ventilation induced lung injury (VILI), disuse atrophy of skeleton muscles, and added to the morbidity and mortality rates for these patients.
- Another approach to artificial lung function, extracorporeal membrane oxygenation (ECMO) constitutes a mechanism for prolonged pulmonary bypass, which has been developed and optimized over several decades but has limited clinical utility today as a state-of-the-art artificial lung. The ECMO system includes an extra-corporeal pump and membrane system that performs a gas transfer across membranes. Despite the numerous advances in the implementation of ECMO over the years, its core technology is unchanged and continues to face important limitations. The limitations of ECMO include the requirement for a large and complex blood pump and oxygenator system, the necessity for a surgical procedure for cannulation, the need for systemic anticoagulation, the labor intensive implementation, the exceeding high cost, and a high rate of complications, including bleeding and infection, protein absorption, and platelet adhesion on the surface of the oxygenator membrane. As a result of these limitations, the ECMO has become limited in its utility to select cases of neonatal respiratory failure, where reversibility is considered to be highly likely.
- One approach to artificial lung functions has been by gas sparing or diffusion of gas across the membrane surface of hollow fibers placed within the blood supply. Previous efforts have achieved some success, and have taught much to pulmonary physiologists, but gas sparing or diffusion has not yet achieved the degree of gas exchanges optimally desired. The development of the intravenous membrane oxygenator (IVOX) presented a natural extension in the artificial lung art, since it was capable of performing intracorporeal gas exchange across an array of hollow fiber membranes situated within the inferior vena cava but did not require any form of blood pump. The insertion of the IVOX effectively introduced a large amount of gas transfer surface area (up to 600 cm2) without alternation of systemic hemodynamics; unfortunately, as with ECMO, the IVOX system has numerous limitations including a moderate rate of achievable gas exchange, difficulty in device implantation, a relatively high rate of adverse events, and a significant rate of device malfunctions, including blood-to-gas leaks due to broken hollow fibers.
- Clinically, there is still a long way to go for us to achieve perfect artificial oxygenation whether in acute patients or long-term care. Therefore, a serious need exists for new technology and therapeutic approaches that have the potential to provide acute, intermediate to chronic, and long-term respiratory support for patients suffering from severe pulmonary failure. There also remains a paramount need for an efficient and inexpensive technology to achieve sustained oxygen concentration in the blood, thereby bypassing the diseased lung without resorting to further damage.
- The present invention is to provide a normal pressure to hyperbaric nano-bubbling intravascular oxygenation system comprising a catheter with single or multiple lumens, a tube wall with numerous nano-sized pores on its surface, capable of being inserted into a blood vessel to transport gas.
-
FIG. 1A , 1B, it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of one lumen type. -
FIG. 2A , 2B, it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multi lumens type. -
FIG. 3 , it is the flowchart to illustrates the method for oxygenation. - Referring to
FIGS. 1A and 1B , it is an embodiment of the present invention to illustrate a normal pressure to hyperbaric intravascular nano-bubbling oxygenator of one lumen type. A partialporous catheter 110 comprises atube wall 111 having lots ofpores 112. Thecatheter 110 is capable of being inserted into a blood vessel. The cross-section area of thecatheter 110 is less than three fourths (¾) of the cross-section area of the blood vessel. The length of thecatheter 110 in a blood vessel varies from person to person depending on patient's body size. Thecatheter 110 comprises the biomaterial, such as, polymer, or ceramic, or metal, or composites. Thetube wall 111 is hydrophobic and able to prevent bacterial colonization and thrombogenesis. The porous area portion of thetube wall 111 is five(5)% to ninety-five(95)% of the entire catheter in the blood vessel. The sizes of the pores are ranged from 0.3 nanometer to five hundred (500) micrometer. - The
catheter 110 includes one closed end and one opening end. The opening end is connected to aconnector 120. - The
connector 120 connects thecatheter 110 and thegas transporting apparatus 130. Thegas transporting apparatus 130 comprises a couple with or without an extended tube and a filter (not shown) for the connection with theconnector 120. Thegas transporting apparatus 130 comprises aflow adjustor 131 with a flow sensor (not shown), apressure adjustor 132 with a barometer (not shown), athermo adjustor 133 with a thermometer (not shown) for these range parameters. - A
pipe 140 connects thegas transporting apparatus 130 and a high pressure gas tank or anyother container 142 with aregulator 141. In an embodiment, the gas is oxygen. Theregulator 141 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator. Thethermo adjustor 133 warms or cools the oxygen to a proper temperature, thepressure adjuster 132 adjusts the pressure of the oxygen, and theflow adjustor 131 controls the flow rate of the oxygen. The oxygen passes theconnector 120 to thetube 110, and then distributes through thepores 112 to the blood. Thepores 112 help produce bubbles in a range of nanometer to micrometer scale for range parameters when transporting gas. - The
control panel 150 calculates the feedback of the measurement of the blood oxygen concentration, vena caval pressure, heart rate, and temperature by one or one more detectors (not shown) and controls thegas transporting apparatus 130 for transporting gas at the specific range of temperature, pressure, and flowrate to thecatheter 110 through theconnector 120. - Referring to
FIG. 2A and 2B , it is an embodiment of the present invention to illustrate a normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multiple lumens type. A partialporous catheter 210 comprises two lumens, onelumen tube wall 211 having lots ofpores 212, the otherlumen tube wall 213 with or without pores, and a separatingwall 214 to separate thetube 210 into thegas lumen 215 with pores on outer tube wall and theliquid lumen 216 with or without pores on the outer tube wall. Each of thegas lumen 215 and theliquid lumen 216 has an opening end with a removable cap (not shown) and thegas lumen 215 connects to aconnector 220. The other end of theliquid lumen 216 comprises an opening end to allow the guide wire or liquid passing through it. The other end of thegas lumen 215 comprises a closed end. Thecatheter 210 is capable of being inserted into a blood vessel. The cross-section area of thecatheter 210 is less than three fourths (¾) of the cross-section area of the blood vessel. The length of thecatheter 210 in a blood vessel varies from person to person depending on patient's body size. Thecatheter 210 comprises the biomaterial, such as, polymer, or ceramic, or metal, or composites. Thetube wall 211 andtube wall 213 are hydrophobic and able to prevent bacterial colonization and thrombogenesis. The porous area portion of thetube wall 211 ortube wall 213 is five(5) % or zero(0)% to ninety-five(95)% of the entire tube in the blood vessel. The sizes of the pores are ranged from 0.3 nanometer to five hundred (500) micrometer. - The
connector 220 connects thegas lumen 215 of thecatheter 210 and thegas transporting apparatus 230. Thegas transporting apparatus 230 comprises a couple with or without an extended tube and a filter (not shown) for the connection with theconnector 220. Thegas transporting apparatus 230 comprises aflow adjustor 231 with a flow sensor (not shown), apressure adjustor 232 with a barometer (not shown), athermo adjustor 233 with a thermometer (not shown) for range parameters. - A
pipe 240 connects thegas transporting apparatus 230 and a high pressure gas tank or anyother container 242 with aregulator 241. In an embodiment, the gas is oxygen. Theregulator 241 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator. Thethermo adjustor 233 warms or cools the oxygen to a proper temperature, thepressure adjuster 232 adjusts the pressure of the oxygen, and theflow adjustor 231 controls the flow rate of the oxygen for range parameters. The oxygen passes theconnector 220 to thegas lumen 215 of thecatheter 210, and then distributes through thepores 212 to the blood. Thepores 212 help produce bubbles in a range of nanometer to micrometer scale when transporting gas. - The
control panel 250 calculates the feedback of the measurement of the blood oxygen concentration, vena caval pressure, heart rate, or temperature by one or one more detectors (not shown) and controls thegas transporting apparatus 230 for transporting gas at the specific range of temperature, pressure, and flowrate to thegas lumen 215 of thecatheter 210 through theconnector 220. - Referring to
FIG. 3 , it is the flowchart to illustrates the method for oxygenation. Atstep 310, a pressurized pure oxygen source is prepared. The oxygen source may be tank containing pressurized pure or high concentration oxygen. Atstep 320, a gas transporting apparatus, including a flow adjuster, a pressure adjuster, and a thermal adjuster to control the range parameters of the gas flow, temperature, and pressure of the oxygen, is connected to a gas lumen of a porous catheter with nano to micro-meter sized pores. Atstep 330, the porous catheter is inserted into a blood vessel of a living body. Atstep 340, the oxygen source is connected to the gas transporting apparatus. Atstep 350, the gas transporting apparatus controls the distribution of the oxygen to the vascular system through the porous catheter. Atstep 360, a blood oxygen concentration, a vena caval pressure, a heart rate, and a temperature of the living body are measured to as the control signals to feedback to the computer in a panel. Atstep 370, The control signals are compared with the predetermined ranges set in the computer, and the panel sends commands to the gas transporting apparatus, and then back to thestep 350. - One skilled in the art will understand that the embodiment of the present invention as shown in the drawings and described above is exemplary only and not intended to be limiting.
- The foregoing description of the preferred embodiment of the present invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form or to exemplary embodiments disclosed. Accordingly, the foregoing description should be regarded as illustrative rather than restrictive. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. The embodiments are chosen and described in order to best explain the principles of the invention and its best mode practical application, thereby to enable persons skilled in the art to understand the invention for various embodiments and with various modifications as are suited to the particular use or implementation contemplated. It is intended that the scope of the invention be defined by the claims appended hereto and their equivalents in which all terms are meant in their broadest reasonable sense unless otherwise indicated. It should be appreciated that variations may be made in the embodiments described by persons skilled in the art without departing from the scope of the present invention as defined by the following claims. Moreover, no element and component in the present disclosure is intended to be dedicated to the public regardless of whether the element or component is explicitly recited in the following claims.
Claims (10)
1. An intravascular nano-bubbling oxygenator, comprising:
a catheter comprising a tube wall having a closed end and an opening end, and capable of being inserted into a blood vessel to transport gaseous oxygen, wherein said tube wall has a hydrophobic outer surface and comprises a plurality of nano-sized pores provided along said tube wall toward said closed end, which are provided with sizes ranging from 0.3 nanometer to 500 micrometer; and said catheter has a cross-section area less than three fourths (¾) of the cross-section area of said blood vessel, wherein said tube wall is arrange for guiding said gaseous oxygen to longitudinally flow from said opening end toward said closed end in order to transversely distribute said gaseous oxygen to produce oxygen bubbles through said nano-sized pores directly inside said blood vessel.
2. The intravascular nano-bubbling oxygenator of claim 1 , wherein said tube wall comprises biomaterial.
3. The intravascular nano-bubbling oxygenator of claim 1 , wherein a porous area of said tube wall is five (5)% to ninety-nine (99)% of said catheter being inserted into a blood vessel.
4. The intravascular nano-bubbling oxygenator of claim 1 , further including a connector provided at said opening end to input said gaseous oxygen into said catheter.
5. The intravascular nano-bubbling oxygenator of claim 7 , further including a gas transporting apparatus connected to said connector.
6. The intravascular nano-bubbling oxygenator of claim 5 , wherein said gas transporting apparatus comprises a flow adjustor, a pressure adjustor, and a thermo adjustor for range parameters.
7. The intravascular nano-bubbling oxygenator of claim 5 , further including a gaseous oxygen source connected to said gas transporting apparatus.
8. The intravascular nano-bubbling oxygenator of claim 7 , wherein said gaseous oxygen source comprises a pipe, a regulator, and a gaseous oxygen container.
9. The intravascular nano-bubbling oxygenator of claim 5 , further including a control panel connected to said gas transporting apparatus to control the inputting of said gaseous oxygen.
10. The intravascular nano-bubbling oxygenator of claim 9 , wherein said control panel controls transporting of said gaseous oxygen by a feedback of measuring a blood oxygen concentration, a vena caval pressure, a heart rate, and a temperature.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/602,260 US20150133853A1 (en) | 2007-10-07 | 2015-01-21 | Intravascular nano-bubbling oxygenator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/868,528 US9101711B2 (en) | 2007-10-07 | 2007-10-07 | Intravascular nano-bubbling oxygenator |
US14/602,260 US20150133853A1 (en) | 2007-10-07 | 2015-01-21 | Intravascular nano-bubbling oxygenator |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/868,528 Continuation US9101711B2 (en) | 2007-10-07 | 2007-10-07 | Intravascular nano-bubbling oxygenator |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150133853A1 true US20150133853A1 (en) | 2015-05-14 |
Family
ID=40523891
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/868,528 Active 2029-01-22 US9101711B2 (en) | 2007-10-07 | 2007-10-07 | Intravascular nano-bubbling oxygenator |
US14/602,260 Abandoned US20150133853A1 (en) | 2007-10-07 | 2015-01-21 | Intravascular nano-bubbling oxygenator |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/868,528 Active 2029-01-22 US9101711B2 (en) | 2007-10-07 | 2007-10-07 | Intravascular nano-bubbling oxygenator |
Country Status (1)
Country | Link |
---|---|
US (2) | US9101711B2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2527075A (en) * | 2014-03-17 | 2015-12-16 | Daassist As | Percutaneous system, devices and methods |
US10893847B2 (en) | 2015-12-30 | 2021-01-19 | Nuheart As | Transcatheter insertion system |
JP6653185B2 (en) * | 2016-02-23 | 2020-02-26 | 泉工医科工業株式会社 | Bubble generator |
CN106377811B (en) * | 2016-08-29 | 2019-11-15 | 安徽通灵仿生科技有限公司 | A kind of vein membrane oxygenation device and oxygen close method |
CN106237414B (en) * | 2016-08-29 | 2019-11-15 | 安徽通灵仿生科技有限公司 | A kind of vein micro-nano mist oxygen device and oxygen therapy method |
CN106215262B (en) * | 2016-08-29 | 2018-11-20 | 安徽通灵仿生科技有限公司 | Oxygenation device and oxygen close method in a kind of venous lumen |
US10537672B2 (en) | 2016-10-07 | 2020-01-21 | Nuheart As | Transcatheter device and system for the delivery of intracorporeal devices |
US10335528B2 (en) | 2016-10-07 | 2019-07-02 | Nuheart As | Transcatheter method and system for the delivery of intracorporeal devices |
US10537670B2 (en) | 2017-04-28 | 2020-01-21 | Nuheart As | Ventricular assist device and method |
US10888646B2 (en) | 2017-04-28 | 2021-01-12 | Nuheart As | Ventricular assist device and method |
CN109621052B (en) * | 2019-01-31 | 2021-06-22 | 陈晓阳 | Intravascular oxygen supply system and method |
US20220080106A1 (en) * | 2020-09-01 | 2022-03-17 | Agitated Solutions Inc. | Intravascular oxygenation system and method |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5261875A (en) * | 1991-02-14 | 1993-11-16 | Wayne State University | Method and apparatus for injection of gas hydrates |
US5336164A (en) * | 1992-01-06 | 1994-08-09 | The Pennsylvania Research Corporation | Intravascular membrane lung apparatus |
US5407426A (en) * | 1991-02-14 | 1995-04-18 | Wayne State University | Method and apparatus for delivering oxygen into blood |
US20030138350A1 (en) * | 1998-05-08 | 2003-07-24 | John Macoviak | Circulatory support system and method of use for isolated segmental perfusion |
US20070131610A1 (en) * | 2005-12-13 | 2007-06-14 | General Electric Company | Membrane-based apparatus and associated method |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5186713A (en) * | 1990-11-01 | 1993-02-16 | Baxter International Inc. | Extracorporeal blood oxygenation system and method for providing hemoperfusion during transluminal balloon angioplasty procedures |
US5376069A (en) * | 1991-03-27 | 1994-12-27 | Hattler; Brack G. | Inflatable percutaneous oxygenator with internal support |
US5478309A (en) * | 1994-05-27 | 1995-12-26 | William P. Sweezer, Jr. | Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery |
US6607698B1 (en) * | 1997-08-15 | 2003-08-19 | Therox, Inc. | Method for generalized extracorporeal support |
US5634892A (en) * | 1995-02-23 | 1997-06-03 | Whalen; Robert L. | Extracorporeal membrane oxygenator |
US6622367B1 (en) * | 1998-02-03 | 2003-09-23 | Salient Interventional Systems, Inc. | Intravascular device and method of manufacture and use |
WO2007127176A2 (en) * | 2006-04-24 | 2007-11-08 | Ekos Corporation | Ultrasound therapy system |
-
2007
- 2007-10-07 US US11/868,528 patent/US9101711B2/en active Active
-
2015
- 2015-01-21 US US14/602,260 patent/US20150133853A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5261875A (en) * | 1991-02-14 | 1993-11-16 | Wayne State University | Method and apparatus for injection of gas hydrates |
US5407426A (en) * | 1991-02-14 | 1995-04-18 | Wayne State University | Method and apparatus for delivering oxygen into blood |
US5336164A (en) * | 1992-01-06 | 1994-08-09 | The Pennsylvania Research Corporation | Intravascular membrane lung apparatus |
US20030138350A1 (en) * | 1998-05-08 | 2003-07-24 | John Macoviak | Circulatory support system and method of use for isolated segmental perfusion |
US20070131610A1 (en) * | 2005-12-13 | 2007-06-14 | General Electric Company | Membrane-based apparatus and associated method |
Also Published As
Publication number | Publication date |
---|---|
US9101711B2 (en) | 2015-08-11 |
US20090093751A1 (en) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9101711B2 (en) | Intravascular nano-bubbling oxygenator | |
Allardet-Servent et al. | Safety and efficacy of combined extracorporeal CO2 removal and renal replacement therapy in patients with acute respiratory distress syndrome and acute kidney injury: the pulmonary and renal support in acute respiratory distress syndrome study | |
JP4897477B2 (en) | Device for automatically measuring pulmonary blood flow in a subject | |
US7135008B2 (en) | Method and apparatus for ultrafiltration utilizing a peripheral access dual lumen venous cannula | |
Quintel et al. | Extracorporeal membrane oxygenation for respiratory failure | |
US20100185136A1 (en) | Method and appartus for controlled reoxygenation | |
Sato et al. | Esophageal P CO 2 as a monitor of perfusion failure during hemorrhagic shock | |
US20080262369A1 (en) | Capnographic Sampling Catheter | |
KR102318993B1 (en) | Carbon dioxide removal system | |
JP2016528965A (en) | Gas exchanger and oxygenator | |
Shenaq et al. | Continuous monitoring of mixed venous oxygen saturation during aortic surgery | |
Samarska et al. | Troubleshooting the rat model of cardiopulmonary bypass: effects of avoiding blood transfusion on long-term survival, inflammation and organ damage | |
Federspiel et al. | Ex vivo testing of the intravenous membrane oxygenator | |
US10086130B2 (en) | Blood oxygenator device | |
Carr et al. | Peritoneal perfusion with oxygenated perfluorocarbon augments systemic oxygenation | |
Crystal et al. | Coronary vasodilation by isoflurane: Abrupt versus gradual administration | |
Ishikawa et al. | Compressing the non-dependent lung during one-lung ventilation improves arterial oxygenation, but impairs systemic oxygen delivery by decreasing cardiac output | |
JP4226217B2 (en) | Apparatus for preparing and transporting oxygen-enriched liquids | |
Gross et al. | Supplemental systemic oxygen support using an intestinal intraluminal membrane oxygenator | |
Kottenberg‐Assenmacher et al. | Minimally invasive endoscopic port‐access™ intracardiac surgery with one lung ventilation: impact on gas exchange and anaesthesia resources | |
Hurtig et al. | Reduction of hypoxic pulmonary vasoconstriction by nitrous oxide administration in the isolated perfused cat lung | |
Johnson et al. | End-respiratory pressure ventilation and sulfobromophthalein sodium excretion in dogs | |
Tönz et al. | Quantitative gas transfer of an intravascular oxygenator | |
Lehtipalo et al. | Effects of positive end‐expiratory pressure on intestinal circulation during graded mesenteric artery occlusion | |
US20070255159A1 (en) | Independent control and regulation of blood gas, pulmonary resistance, and sedation using an intravascular membrane catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |